DocStoX is a free AI-powered research platform for Indian equity markets, covering 6,800+ NSE & BSE stocks with prices, fundamentals, 326 financial ratios, shareholding, FII/DII flows, F&O, IPOs, a visual screener and AI stock scoring.

Yes. DocStoX has a free tier covering stock research, the screener, FII/DII data and educational guides, plus a free MCP API tier (50 tool calls/day) for AI assistants. A Pro plan adds higher limits and advanced features.

What data does DocStoX cover?

Every NSE & BSE listed stock (6,800+ instruments): EOD and intraday prices, income statement / balance sheet / cash flow, 326 ratios, quarterly shareholding, promoter pledge, mutual-fund holdings, FII/DII flows, F&O and option-chain data, analyst forecasts, IPOs, corporate actions and news.

Can AI assistants like ChatGPT or Claude use DocStoX data?

Yes. DocStoX runs a public Model Context Protocol (MCP) server at https://mcp.docstox.com/mcp with 39 tools, so Claude, ChatGPT, Cursor and other MCP clients can pull Indian market data directly. Setup and a free key are at https://docstox.com/mcp.

Neutral impactCompany

CORONA Remedies Limited — Analyst/Investor Meet Para A-XBRL

NSE 2 hrs ago·20 Aug 2026, 11:52 am

Corona Remedies

Corona Remedies Limited has announced a meeting with analysts and institutional investors, scheduled for the Para-A segment of its XBRL filing. This disclosure signals the company's intent to engage with the financial community and is a standard procedural update.

For investors, such meetings often provide a platform for management to discuss business performance, future strategy, or address market queries. While the agenda is not specified, the event offers a window into the company's outlook, which could influence market sentiment.

Investors should monitor the company's official communications for any specific updates or key takeaways from the discussions. Keeping an eye on the company's future disclosures will help gauge the impact of this engagement on its stock performance.